骨髓纤维化患者采用替代供体可改善移植结果：20年日本供体来源登记分析和鲁索利替尼的影响

IF 10.1 1区医学 Q1 HEMATOLOGY

American Journal of Hematology Pub Date : 2025-05-01 DOI:10.1002/ajh.27699

Kazuki Sakatoku, Hirohisa Nakamae, Makoto Murata, Yutaka Shimazu, Katsuto Takenaka, Fumihiko Kimura, Naoyuki Uchida, Tetsuya Nishida, Takahiro Fukuda, Noriko Doki, Jun Ishikawa, Emiko Sakaida, Keisuke Kataoka, Shuichi Shirane, Masatsugu Tanaka, Hikaru Kobayashi, Masashi Sawa, Toshio Wakayama, Noboru Asada, Yasufumi Uehara, Makoto Yoshimitsu, Junya Kanda, Marie Ohbiki, Yoshiko Atsuta, Takayoshi Tachibana

{"title":"骨髓纤维化患者采用替代供体可改善移植结果：20年日本供体来源登记分析和鲁索利替尼的影响","authors":"Kazuki Sakatoku, Hirohisa Nakamae, Makoto Murata, Yutaka Shimazu, Katsuto Takenaka, Fumihiko Kimura, Naoyuki Uchida, Tetsuya Nishida, Takahiro Fukuda, Noriko Doki, Jun Ishikawa, Emiko Sakaida, Keisuke Kataoka, Shuichi Shirane, Masatsugu Tanaka, Hikaru Kobayashi, Masashi Sawa, Toshio Wakayama, Noboru Asada, Yasufumi Uehara, Makoto Yoshimitsu, Junya Kanda, Marie Ohbiki, Yoshiko Atsuta, Takayoshi Tachibana","doi":"10.1002/ajh.27699","DOIUrl":null,"url":null,"abstract":"This study of 308 myelofibrosis patients shows that in recent years (2013–2019), alternative donors (mismatched unrelated donors and cord blood) achieved survival rates comparable to HLA-matched donors—a significant improvement compared to earlier years (2000–2012) when outcomes differed substantially. Ruxolitinib showed significant benefits in older patients (≥ 57), particularly with mismatched unrelated donors. Cord blood transplantation outcomes improved with MMF-based GVHD prophylaxis. These findings suggest optimized strategies combining both age-specific and donor-specific approaches can maximize transplant success in myelofibrosis patients.","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"15 1","pages":""},"PeriodicalIF":10.1000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Improved Transplant Outcomes With Alternative Donors in Myelofibrosis: A 20-Year Japanese Registry Analysis of Donor Sources and the Impact of Ruxolitinib\",\"authors\":\"Kazuki Sakatoku, Hirohisa Nakamae, Makoto Murata, Yutaka Shimazu, Katsuto Takenaka, Fumihiko Kimura, Naoyuki Uchida, Tetsuya Nishida, Takahiro Fukuda, Noriko Doki, Jun Ishikawa, Emiko Sakaida, Keisuke Kataoka, Shuichi Shirane, Masatsugu Tanaka, Hikaru Kobayashi, Masashi Sawa, Toshio Wakayama, Noboru Asada, Yasufumi Uehara, Makoto Yoshimitsu, Junya Kanda, Marie Ohbiki, Yoshiko Atsuta, Takayoshi Tachibana\",\"doi\":\"10.1002/ajh.27699\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This study of 308 myelofibrosis patients shows that in recent years (2013–2019), alternative donors (mismatched unrelated donors and cord blood) achieved survival rates comparable to HLA-matched donors—a significant improvement compared to earlier years (2000–2012) when outcomes differed substantially. Ruxolitinib showed significant benefits in older patients (≥ 57), particularly with mismatched unrelated donors. Cord blood transplantation outcomes improved with MMF-based GVHD prophylaxis. These findings suggest optimized strategies combining both age-specific and donor-specific approaches can maximize transplant success in myelofibrosis patients.\",\"PeriodicalId\":7724,\"journal\":{\"name\":\"American Journal of Hematology\",\"volume\":\"15 1\",\"pages\":\"\"},\"PeriodicalIF\":10.1000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/ajh.27699\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ajh.27699","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

这项对308名骨髓纤维化患者的研究表明，近年来（2013-2019年），替代献血者（不匹配的非亲属献血者和脐带血）的生存率与hla匹配的献血者相当，与早期（2000-2012年）相比，这是一个显著的改善，而早期的结果存在很大差异。Ruxolitinib在老年患者（≥57岁）中显示出显著的益处，特别是不匹配的非亲属供体。基于mmf的GVHD预防改善了脐带血移植结果。这些发现表明，结合年龄特异性和供体特异性方法的优化策略可以最大限度地提高骨髓纤维化患者的移植成功率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Improved Transplant Outcomes With Alternative Donors in Myelofibrosis: A 20-Year Japanese Registry Analysis of Donor Sources and the Impact of Ruxolitinib

查看原文本刊更多论文

Improved Transplant Outcomes With Alternative Donors in Myelofibrosis: A 20-Year Japanese Registry Analysis of Donor Sources and the Impact of Ruxolitinib

This study of 308 myelofibrosis patients shows that in recent years (2013–2019), alternative donors (mismatched unrelated donors and cord blood) achieved survival rates comparable to HLA-matched donors—a significant improvement compared to earlier years (2000–2012) when outcomes differed substantially. Ruxolitinib showed significant benefits in older patients (≥ 57), particularly with mismatched unrelated donors. Cord blood transplantation outcomes improved with MMF-based GVHD prophylaxis. These findings suggest optimized strategies combining both age-specific and donor-specific approaches can maximize transplant success in myelofibrosis patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American Journal of Hematology 医学-血液学

CiteScore

15.70

自引率

3.90%

发文量

363

审稿时长

3-6 weeks

期刊介绍： The American Journal of Hematology offers extensive coverage of experimental and clinical aspects of blood diseases in humans and animal models. The journal publishes original contributions in both non-malignant and malignant hematological diseases, encompassing clinical and basic studies in areas such as hemostasis, thrombosis, immunology, blood banking, and stem cell biology. Clinical translational reports highlighting innovative therapeutic approaches for the diagnosis and treatment of hematological diseases are actively encouraged.The American Journal of Hematology features regular original laboratory and clinical research articles, brief research reports, critical reviews, images in hematology, as well as letters and correspondence.